AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 181 min read$DVA

DaVita (NYSE: DVA) director Phyllis Yale gets 278-share stock award

DaVita (DVA) reported that director Phyllis R. Yale received a grant of 278 shares of common stock on 2026-08-15, with no transaction price. She now directly holds 9,803 shares. The filing did not report any sales or derivative transactions.

Original reporting
stocktitan.net
Published Aug 18, 2026, 10:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 11:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$DVA
Neutral
high confidence
Mentioned
$DVA
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

The transaction adds 278 shares to a director's holdings, a routine event with no immediate market impact.

02

Market read

Minimal relevance; the filing is a routine insider compensation disclosure.

03

What to watch

Potential future larger grants or insider activity could be more relevant.

Relevance 4/10Novelty 3/10Timing: post‑market filing on 2026-08-15

Background

Form 4 filings disclose insider transactions; this award is a standard compensation grant.

Company-level read

Ticker impact

$DVANeutralHigh confidence
Context

Director Phyllis Yale received a grant of 278 DaVita shares on 2026-08-15, increasing her direct holding to 9,803 shares.

Expected impact

No material price movement expected.

Evidence & confidence

Small, non‑monetary grant to a board member; similar past awards have not moved the share price.

Market effects

Sector

None; the award does not affect the healthcare services sector.

Regional

None; limited to DaVita shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider grants can signal confidence, but the size is too trivial to act on.

Key entities

  • Company
    DaVita Inc.

    US‑listed dialysis provider (NYSE:DVA).

  • Individual
    Phyllis R. Yale

    Director of DaVita receiving the grant.

Read at source← All news

Related articles

AUG 27
$DVAMedAI 8/10

Warren Buffett and Greg Abel Quietly Hold a Bigger Percentage of This Company Than Any Other in Berkshire's Portfolio (Hint: It's Not Apple or American Express)

Berkshire Hathaway's largest proportional holding is in DaVita (DVA), a kidney dialysis center operator, with a 45% stake. Berkshire has reduced its position from 36.1 million to 28.7 million shares since early 2025. DaVita's stock is up 56% year-to-date, with Q1 revenue of $3.4 billion and adjusted profit of $198 million. The company raised its EPS guidance to $14.10-$15.20.

fool.com2 min
AUG 8
$DVAMed

DaVita Shares Rise After TD Cowen Upgrades Stock to Buy

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

yahoo.com5 min
AUG 7
$DVAMed

Why is DaVita stock up 2% today?

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

investing.com3 min
AUG 6
$DVAMed

DaVita Inc. Q2 2026 Earnings Call Summary

DaVita reported Q2 2026 updates on dialysis operations, citing improved patient mortality and a Medicare bundle shift that reduced reliance on OTC phosphate binders by over 50%. Revenue per treatment fell sequentially. DaVita reconfirmed 2026 adjusted operating income guidance of $2.2B and expects 2026 treatment growth at the top of 25-50 bps. FDA approval of NIPRO expanded HD dialyzers may improve supply.

yahoo.com7 min